US20150064158A1 - Sense-improving agent - Google Patents
Sense-improving agent Download PDFInfo
- Publication number
- US20150064158A1 US20150064158A1 US13/981,698 US201213981698A US2015064158A1 US 20150064158 A1 US20150064158 A1 US 20150064158A1 US 201213981698 A US201213981698 A US 201213981698A US 2015064158 A1 US2015064158 A1 US 2015064158A1
- Authority
- US
- United States
- Prior art keywords
- milk
- basic protein
- protein fraction
- derived basic
- sensation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 157
- 235000013336 milk Nutrition 0.000 claims abstract description 152
- 239000008267 milk Substances 0.000 claims abstract description 152
- 210000004080 milk Anatomy 0.000 claims abstract description 152
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000035945 sensitivity Effects 0.000 claims description 65
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 14
- 108091005804 Peptidases Proteins 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 14
- 239000003729 cation exchange resin Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 108090000317 Chymotrypsin Proteins 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 229960002376 chymotrypsin Drugs 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 229960001322 trypsin Drugs 0.000 claims description 4
- 230000035807 sensation Effects 0.000 abstract description 49
- 230000006866 deterioration Effects 0.000 abstract description 42
- 230000002093 peripheral effect Effects 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 12
- 235000019615 sensations Nutrition 0.000 description 43
- 239000000203 mixture Substances 0.000 description 30
- 230000008058 pain sensation Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000005096 rolling process Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 102000010445 Lactoferrin Human genes 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003061 neural cell Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101100065878 Caenorhabditis elegans sec-10 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- -1 ester compound Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 108010073128 phosphatidylcholine-specific phospholipase C Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A23K1/1631—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A23L1/3056—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/23—Aspartic endopeptidases (3.4.23)
- C12Y304/23002—Pepsin B (3.4.23.2)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Definitions
- the invention relates to a skin sensitivity improving agent that includes a basic protein fraction or a degraded basic protein fraction as an active ingredient and improves deterioration in peripheral sensation, and a skin sensitivity improving food, drink, feed, or cosmetic that includes the skin sensitivity improving agent.
- Deterioration in peripheral sensation can be known as one of the age-related symptoms.
- the deterioration in peripheral sensation also occurs due to not only aging, but also diseases such as diabetes and the like.
- Deterioration in peripheral sensation may occur following troubles; for example, as it can't feel hot immediately when touching a hot object, a risk of burns or the like increases or the discovery of an injury becomes delay due to deterioration in pain sensation.
- studies that improve deterioration in peripheral sensation due to ageing or diseases have been conducted.
- sphingomyelinase or phosphatidylcholine-specific phospholipase C which are enzymes that increase biosynthesis of endogenous ceramides promote differentiation of PC-12 cells which is one of the neural cell lines through the secretion of neurotrophic factors from Swiss 3T3 fibroblast cells.
- ceramides and the above enzymes are not food ingredients, it is necessary to take account of safety. Therefore, a safe agent that is effective to improve deterioration in peripheral sensation through daily intake or skin application has been desired.
- Patent Document 1 JP-A-H08-151331
- Patent Document 2 JP-A-2003-146883
- Non-patent Document 1 Norimichi Nakahata and Satoko Okubo, Studies on Expression Mechanism of Physiological Functions of Ceramides Having Skin Protection Function, Annual Report of Cosmetology, Vol. 10, 2002
- An object of the present invention is to provide a safe and skin sensitivity improving agent that is effective to improve deterioration in peripheral sensation through daily intake or skin application.
- Another object of the present invention is to provide a sensation-improving food, drink, feed, or cosmetic that is effective to improve deterioration in peripheral sensation through oral intake or skin application.
- milk-derived basic protein fraction a basic protein fraction derived from milk
- degraded milk-derived basic protein fraction a degraded basic protein fraction obtained by degrading the milk-derived basic protein fraction using a protease
- the inventors thus completed a skin sensitivity improving agent by utilizing the milk-derived basic protein fraction and/or the degraded milk-derived basic protein fraction as an active ingredient.
- a skin sensitivity improving food, drink, feed, or cosmetic can be obtained by adding the skin sensitivity improving agent to a food, drink, feed, or the like, respectively.
- the invention provides the following.
- a skin sensitivity improving agent including a milk-derived basic protein fraction as an active ingredient.
- a skin sensitivity improving agent including a degraded milk-derived basic protein fraction as an active ingredient, the degraded milk-derived basic protein fraction being obtained by treating the milk-derived basic protein fraction according to any one of (1) to (3) with a protease.
- protease is at least one protease selected from the group consisting of pepsin, trypsin, chymotrypsin, and pancreatin.
- a skin sensitivity improving food, drink, feed, or cosmetic including the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction according to any one of (1) to (5).
- a method for improving sensation of a mammal including administering a composition that includes a milk-derived basic protein fraction to the mammal via oral administration or application on skin.
- a method for improving sensation of a mammal including administering a composition that includes a degraded milk-derived basic protein fraction to the mammal via oral administration or application on skin, the degraded milk-derived basic protein fraction being obtained by treating the milk-derived basic protein fraction according to any one of (7) to (9) with a protease.
- protease is at least one protease selected from the group consisting of pepsin, trypsin, chymotrypsin, and pancreatin.
- the invention can thus provide a skin sensitivity improving agent that includes a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction as an active ingredient, and a skin sensitivity improving food, drink, feed, or cosmetic that includes a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction.
- the skin sensitivity improving agent according to the invention exhibits an effect that improves deterioration in peripheral sensation.
- the invention is characterized in that a milk-derived basic protein fraction or a degraded milk-derived basic protein fraction are used as active ingredients.
- the milk-derived basic protein fraction is obtained from mammalian milk such as cow milk, human milk, goat milk, or ewe milk, and the degraded milk-derived basic protein fraction is obtained by treating the milk-derived basic protein fraction with a protease.
- the milk-derived basic protein fraction has the following properties.
- the milk-derived basic protein fraction comprises several types of proteins having a molecular weight of 3,000 to 80,000 determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
- the milk-derived basic protein fraction includes proteins in an amount of 95 wt % or more, and includes a small amount of fats and ash.
- the milk-derived basic protein fraction mainly includes lactoferrin and lactoperoxidase as proteins.
- the milk-derived basic protein fraction has basic amino acids, such as lysine, histidine, arginine and the like in an amount of 15 wt % or more based on the total amino acids.
- the basic protein fraction may be obtained by applying a milk-derived raw material, such as skim milk, whey or the like to a cation-exchange resin to adhered the basic proteins on the cation-exchange resin, eluting the basic protein fraction adhered on the cation-exchange resin by using an eluant having a sodium chloride concentration of 0.1 to 1 M, collecting the eluted fraction, which is desalted and concentrated by using a reverse osmosis (RO) membrane, electrodialysis (ED), or the like, and optionally drying the resulting product, for example.
- a milk-derived raw material such as skim milk, whey or the like
- a cation-exchange resin to adhered the basic proteins on the cation-exchange resin
- eluant having a sodium chloride concentration of 0.1 to 1 M collecting the eluted fraction, which is desalted and concentrated by using a reverse osmosis (RO) membrane, electrodialysis (ED
- the following methods have been known as a method of obtaining a milk-derived basic protein fraction; a method of obtaining the fraction by contacting milk or a milk-derived raw material with a cation exchanger to adhere on the cation exchanger, and eluting the basic protein fraction adhered on the cation exchanger using an eluant having a pH of more than 5 and an ionic strength of more than 0.5 (JP-A-5-202098), a method of obtaining the fraction using an alginic acid gel (JP-A-61-246198), a method of obtaining the fraction from whey using porous inorganic particles (JP-A-1-86839), a method of obtaining the fraction from milk using a sulfated ester compound (JP-A-63-255300), or the like.
- a basic protein fraction obtained by such a method may be used in the invention.
- the degraded milk-derived basic protein fraction has the same amino acid composition as that of the milk-derived basic protein fraction.
- the degraded milk-derived basic protein fraction may be obtained as a peptide composition having an average molecular weight of 4,000 or less by treating a milk-derived basic protein fraction obtained by the above methods with a protease such as pepsin, trypsin, or chymotrypsin, and optionally treating the resulting product with a protease such as pancreatin or the like.
- the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction may be used directly as the skin sensitivity improving agent according to the invention.
- the skin sensitivity improving agent may be further mixed a raw material or the like that is normally used for drugs, food, drink, and feed, such as saccharides, lipids, proteins, vitamins, minerals, or flavors, or the like, in addition to the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction, and the skin sensitivity improving agent may be prepared into a powdered drug, granules, a tablet, a capsule, a drinkable preparation, or the like by a conventional method.
- the skin sensitivity improving agent may also be used in common application form such as emulsion, cream, lotion, massage mask, or the like.
- the skin sensitivity improving agent in preparation form may be prepared by a conventional method while appropriately adding the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction used as an active ingredient in the invention, and may be used as a cosmetic.
- Another component e.g., ceramide, sphingomyelinase, or sphingomyelin or the like that exhibits a skin sensitivity improving effect may be used in combination with the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction.
- the peripheral sensation was improved by orally administering the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/kg weight or more, and preferably 20 mg/kg weight or more per mouse.
- the skin liniment may contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.001 to 40 wt %, and preferably 0.1 to 10 wt %, based on the total amount of the skin liniment.
- a skin sensitivity improving food or drink according to the invention may be produced by mixing the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction to a normal food or drink, such as yogurt, milk-based drink, wafer, dessert or the like. It is preferable that the skin sensitivity improving food or drink contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.5 to 2000 mg per 100 g of the food or drink so that an adult can take the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/day or more, although the content of the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is appropriately determined depending on the type of the food or drink.
- a skin sensitivity improving feed according to the invention may be produced by adding the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction to a normal feed, such as livestock feed, pet food or the like. It is preferable that the skin sensitivity improving feed contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 0.5 to 2000 mg per 100 g of the feed so that the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is taken in an amount of 10 mg/day or more.
- the method of mixing the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction may not be particularly limited.
- the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is suspended or dissolved in deionized water, and the mixture is stirred and prepared in the form of a drug, food, drink, or feed.
- the stirring/mixing conditions are not particularly limited as long as the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction is uniformly mixed.
- the mixture may be stirred/mixed using an ultra-disperser, a TK-homomixer, or the like.
- the solution containing the composition may optionally be concentrated using an RO membrane, or freeze-dried so that the solution can be easily used for a drug, food, drink, or feed.
- a sterilization treatment conventionally used in the production of a drug, food, drink, or feed may be employed in the invention. Dry-heat sterilization may also be employed for a powdery product. Therefore, it is possible to produce drugs, food, drink, and feed in various forms (e.g., liquid, gel, powder, or granules) that contain the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction of the invention.
- a column (diameter: 5 cm, height: 30 cm) filled with 400 g of sulfonated Chitopearl (cation-exchange resin; manufactured by Fuji Spinning Co., Ltd.) was sufficiently washed with deionized water.
- 40 1 (liters) of unsterilized skim milk (pH 6.7) was passed through the column at a flow rate of 25 ml/min.
- the column was then sufficiently washed with deionized water, and a basic protein fraction adhered on the resin was eluted with a 0.02 M carbonate buffer solution (pH 7.0) containing 0.98 M sodium chloride.
- the eluate was desalted and concentrated using a reverse osmosis (RO) membrane, and freeze-dried to obtain 21 g of powdery milk-derived basic protein fraction (Example product 1).
- the molecular weight of the milk-derived basic protein fraction determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was distributed in the range of 3000 to 80,000.
- the milk-derived basic protein fraction had the composition shown in Table 1.
- the milk-derived basic protein fraction was hydrolyzed using 6 N hydrochloric acid at 110° C. for 24 hours, and the amino acid composition of the milk-derived basic protein fraction was analyzed using an amino acid analyzer (“L-8500” manufactured by Hitachi Ltd.). The results are shown in Table 2.
- the protein composition of the milk-derived basic protein fraction was analyzed by ELI SA. As shown in Table 3, the milk-derived basic protein fraction had a lactoferrin content and a lactoperoxidase content of 40% or more.
- the basic protein fraction may be used directly as the skin sensitivity improving agent according to the invention.
- a column (diameter: 100 cm, height: 10 cm) filled with 30 kg of cation-exchange resin (SP Toyopearl; manufactured by Tosoh Corporation) was sufficiently washed with deionized water.
- the column was then sufficiently washed with deionized water, and a basic protein fraction adhered on the resin was eluted with a 0.1 M citrate buffer solution (pH 5.7) containing 0.9 M sodium chloride.
- the eluate was desalted and concentrated by electrodialysis (ED), and freeze-dried to obtain 183 g of a powdery milk-derived basic protein fraction (Example product 2).
- the milk-derived basic protein fraction thus obtained may be used directly as the skin sensitivity improving agent according to the invention.
- Example product 3 50 g of the milk-derived basic protein fraction obtained in Example 1 was dissolved in 10 1 of distilled water. After the addition of 1% pancreatin (manufactured by Sigma), the mixture was reacted at 37° C. for 2 hours. After completion of the reaction, the protease was inactivated by heating the mixture at 80° C. for 10 minutes to obtain 48.3 g of a degraded milk-derived basic protein fraction (Example product 3). The degraded milk-derived basic protein fraction thus obtained may be used directly as the skin sensitivity improving agent according to the invention.
- Swiss 3T3 cells which is one of the fibroblast cell lines known to be present in skin, were cultured for 2 days under the condition that Example product 1 of the milk-derived basic protein fraction or Example product 3 of the degraded milk-derived basic protein fraction was added at a concentration of 0.03 to 1%, respectively (Example product 1: group A, Example product 3: group B).
- Swiss 3T3 cells were cultured for 2 days without adding Example product 1 of the milk-derived basic protein fraction or Example product 3 of the degraded milk-derived basic protein fraction (group C).
- PC-12 cells which is one of the neural cell lines, were cultured adding the culture medium of Swiss 3T3 cells, and morphological differentiation of the PC-12 cells was observed.
- PC-12 cells were highly differentiated when adding the culture mediums of the group A or B.
- the above experiment was repeated several times, and the differentiation ratio was determined using an optical microscope. It was confirmed that 95% or more of the cells were differentiated in both cases of group A and B. In contrast, PC-12 cells were not differentiated when adding the culture medium of the group C. No differentiation was observed using an optical microscope when the experiment was repeated several times. It was thus confirmed that the milk-derived basic protein fraction obtained in Example 1 and the degraded milk-derived basic protein fraction obtained in Example 3 promoted differentiation of PC-12 cells which is one of the neural cell lines.
- a skin sensitivity improving effect was evaluated by the hot plate test that is a thermal stimulation behavioristic approach developed by Woolfe and MacDonald.
- 24-week-old hairless mice (Hos:HR-1) were divided into three groups (10 mice/group).
- Example product 2 milk-derived basic protein fraction
- Example product 2 milk-derived basic protein fraction
- Each mouse was placed on a hot plate at 54° C., and the time elapsed until the mouse made an escape behavior such as taking off the foot from the hot plate, standing up, or jumping was measured.
- the maximum time of escape behavior positive reaction time that is time until the mouse made an escape behavior after applying thermal stimulation was set to 30 seconds. When the escape behavior positive reaction time was 30 seconds or more, the escape behavior positive reaction time was determined to be 30 seconds. The results are shown in Table 4.
- Example product 2 milk-derived basic protein fraction
- Example product 2 milk-derived basic protein fraction
- Healthy elderly persons (average age: 75 ⁇ 3) who suffered deterioration in sensation in the hands were divided into following five groups (10 subjects/group).
- the pain sensation was evaluated using five pins having different thickness at five fulcrum positions.
- the thinnest pin 1 was rolled along the medial side of the arm, and the subject was asked about the degree of normal pain sensation.
- the pin 1 was then rolled along the palm and the bottom of the foot while sequentially changing the holder fulcrum position to determine the fulcrum position at which the same pain sensation degree as the first pain sensation occurred. (Evaluation method)
- the algesiometer is designed so that the pain sensation occurs to the same extent between when rolling the pin 1 (fulcrum: 50 g) along the medial side of the arm and when rolling the pin 2 (fulcrum: 50 g) along the palm.
- the pain sensation was evaluated as follows in accordance with the instruction manual. The pain sensation was evaluated by points, and the average points were calculated.
- Example product 1 milk-derived basic protein fraction
- Example product 3 degraded milk-derived basic protein fraction
- Example product 1 milk-derived basic protein fraction
- Example product 3 degraded milk-derived basic protein fraction
- Deterioration in sensation is expected to be improved when an adult takes the milk-derived basic protein fraction or the degraded milk-derived basic protein fraction in an amount of 10 mg/day or more generally, and preferably 20 mg/day or more.
- a skin sensitivity improving cosmetic was prepared by mixing the degraded milk-derived basic protein fraction (Example product 3) obtained in Example 3 with the raw materials in the ratio shown in Table 9.
- Healthy elderly persons who suffered deterioration in sensation in the hands were divided into groups A and B (15 subjects/group).
- the subjects of the group A were applied the cosmetic (cream) that was prepared in the same manner as Example product 4, but did not contain a skin sensitivity improving agent, once daily to whole of the hands and the feet thereof, and the subjects of the group B were applied the skin sensitivity improving cosmetic (cream) obtained in Example 4 once daily to whole of the hands and the feet thereof.
- the application period was 6 weeks.
- the pain sensation in the palm and the arch of the foot was measured by 4 criteria (normal, deterioration I, deterioration II, or deterioration III) before the application and after the application for 6 weeks with respect to the pain sensation in the medial side of the arm using a pain/touch-pressure sensation measuring device (Algesiometer; manufactured by Intercross Ltd.) in accordance with the instruction manual. After the completion of the application for 6weeks, a questionnaire survey on an improvement in sensation in the hands was carried out to each subject. The results are shown in Tables 10 to 13. The measurement was performed in the same manner as in Test Example 3.
- the sensation in the palm and the bottom of the foot tended to be improved by applying the skin sensitivity improving cosmetic (cream) of Example product 4 . It was thus confirmed that deterioration in sensation, particularly peripheral sensation, is expected to be improved by applying cream that includes the skin sensitivity improving agent according to the invention.
- Example product 1 milk-derived basic protein fraction
- Example product 1 milk-derived basic protein fraction
- deionized water deionized water
- the solution was stirred by a TK-homomixer (“TK ROBO MICS” manufactured by PRIMIX Corporation) at 6000 rpm for 30 minutes to obtain a basic protein fraction solution having a basic protein fraction content of 100 mg/100 g. 4.0 kg of casein, 5.0 kg of a soybean protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 18.0 kg of dextrin, 6.0 kg of a mineral mixture, 1.95 kg of a vitamin mixture, 2.0 kg of an emulsifying agent, 4.0 kg of a stabilizer, and 0.05 kg of essence were added to 5.0 kg of the milk-derived basic protein fraction solution.
- TK ROBO MICS manufactured by PRIMIX Corporation
- a retort pouch (200 ml) was filled with the mixture.
- the mixture was then sterilized using a retort sterilizer (class-1 pressure vessel, “RCS-4CRTGN” manufactured by Hisaka Works, Ltd.) at 121° C. for 20 minutes to obtain 50 kg of a skin sensitivity improving liquid nutrient composition.
- the resulting skin sensitivity improving liquid nutrient composition was not observed any precipitation and the like, and did not exhibit abnormal flavor.
- the skin sensitivity improving liquid nutrient composition contained the milk-derived basic protein fraction in an amount of 10 mg/100 g.
- Example product 2 milk-derived basic protein fraction
- Example product 2 milk-derived basic protein fraction
- the solution was stirred using an ultra-disperser (“ULTRA-TURRAX T-25” manufactured by IKA Japan) at 9500 rpm for 30 minutes.
- 40 g sorbitol, 2 g of a sour agent, 2 g of essence, 5 g of pectin, 5 g of whey protein concentrate, 1 g of calcium lactate, and 235 g of deionized water were added to the solution. After stirring the mixture, the mixture was filled in a cheer pack (200 ml). After sterilizing the mixture at 85° C.
- the skin sensitivity improving gel-like food contained the milk-derived basic protein fraction in an amount of 200 mg/100 g.
- Example product 3 degraded milk-derived basic protein fraction
- the solution was stirred using an ultra-disperser (“ULTRA-TURRAX T-25” manufactured by IKA Japan) at 9500 rpm for 30 minutes.
- the resulting mixture was filled into a glass bottle (100 ml).
- the bottle was sealed to obtain ten bottles of skin sensitivity improving drink (100 ml/ bottle).
- the resulting skin sensitivity improving drink was not observed any precipitation, and did not exhibit abnormal flavor.
- the skin sensitivity improving drink contained the degraded milk-derived basic protein fraction in an amount of 400 mg/100 g.
- Example product 3 degraded milk-derived basic protein fraction
- Example product 3 degraded milk-derived basic protein fraction
- the solution was stirred using a TK-homomixer (“MARK II 160” manufactured by PRIMIX Corporation) at 3600 rpm for 40 minutes to obtain a degraded milk-derived basic protein fraction solution containing the degraded milk-derived basic protein fraction in an amount of 2 g/100 g.
- MARK II 160 manufactured by PRIMIX Corporation
- the raw materials were mixed in the ratio shown in Table 14. 1 g of the resulting mixture was formed and tableted by a conventional method to obtain a skin sensitivity improving agent of the invention.
- the skin sensitivity improving agent contained the milk-derived basic protein fraction in an amount of 100 mg/g.
- a skin sensitivity improving cosmetic (lotion) was prepared by mixing the raw materials in the ratio shown in Table 15.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011014441 | 2011-01-26 | ||
| JP2011-014441 | 2011-01-26 | ||
| PCT/JP2012/050617 WO2012102100A1 (ja) | 2011-01-26 | 2012-01-13 | 感覚改善剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2012/050617 A-371-Of-International WO2012102100A1 (ja) | 2011-01-26 | 2012-01-13 | 感覚改善剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/850,485 Division US9884095B2 (en) | 2011-01-26 | 2015-09-10 | Milk-derived basic protein fraction as skin sensitivity improving agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20150064158A1 true US20150064158A1 (en) | 2015-03-05 |
Family
ID=46580672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/981,698 Abandoned US20150064158A1 (en) | 2011-01-26 | 2012-01-13 | Sense-improving agent |
| US14/850,485 Expired - Fee Related US9884095B2 (en) | 2011-01-26 | 2015-09-10 | Milk-derived basic protein fraction as skin sensitivity improving agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/850,485 Expired - Fee Related US9884095B2 (en) | 2011-01-26 | 2015-09-10 | Milk-derived basic protein fraction as skin sensitivity improving agent |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150064158A1 (ja) |
| EP (1) | EP2668956A4 (ja) |
| JP (1) | JP5993308B2 (ja) |
| KR (1) | KR101748907B1 (ja) |
| CN (1) | CN103370074B (ja) |
| AU (1) | AU2012210013C1 (ja) |
| CA (1) | CA2823505A1 (ja) |
| MY (1) | MY162943A (ja) |
| TW (1) | TWI562734B (ja) |
| WO (1) | WO2012102100A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012319579B2 (en) * | 2011-10-04 | 2017-08-10 | Megmilk Snow Brand Co., Ltd. | Sense-improving agent |
| US9861121B2 (en) | 2013-03-28 | 2018-01-09 | Megmilk Snow Brand Co., Ltd. | Milk basic protein composition and production process therefor |
| US9884095B2 (en) | 2011-01-26 | 2018-02-06 | Megmilk Snow Brand Co., Ltd. | Milk-derived basic protein fraction as skin sensitivity improving agent |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE901672A (fr) | 1985-02-07 | 1985-08-07 | Oleofina Sa | Procede de purification de proteines du lait et de ses derives. |
| JPH0725800B2 (ja) | 1987-04-10 | 1995-03-22 | 雪印乳業株式会社 | 硫酸エステル化物を用いて乳からラクトフエリンを分離、精製する方法 |
| FR2616628B1 (fr) | 1987-06-19 | 1989-09-29 | Entremont Sa | Procede pour extraire des proteines du lactoserum par adsorption et elution |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| CA2005600A1 (en) * | 1988-12-20 | 1990-06-20 | Cal-Henrik Heldin | Endothelial cell growth factor |
| US5756686A (en) | 1988-12-20 | 1998-05-26 | Ludwig Institute For Cancer Research | Peptides derived from endothelial cell growth factor |
| JPH0389629A (ja) * | 1989-08-31 | 1991-04-15 | Fujitsu Ltd | アナログ―デジタルコンバータ |
| CA2086681C (en) | 1990-07-13 | 2004-01-06 | Francis J. Ballard | Growth promoting agent derived from milk |
| JP2947657B2 (ja) * | 1991-02-27 | 1999-09-13 | 森永乳業株式会社 | 神経成長因子産生促進剤 |
| CA2123685C (en) | 1991-11-25 | 2003-10-07 | Hans-Arne Hansson | Medicament for promoting growth of mammalian nerve |
| JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
| NZ253867A (en) * | 1992-06-12 | 1996-08-27 | Cephalon Inc | Treating peripheral neuropathy using igf-1 or igf-3 |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| JP3112637B2 (ja) | 1994-09-30 | 2000-11-27 | 雪印乳業株式会社 | 骨強化剤 |
| AUPQ878600A0 (en) * | 2000-07-13 | 2000-08-03 | Gropep Pty Ltd | Compositions and methods for the treatment of intact skin |
| US20030040475A1 (en) * | 2001-01-16 | 2003-02-27 | Yasuhiro Toba | Agents for improving lipid metabolism and reducing high blood pressure |
| JP2003089629A (ja) * | 2001-09-18 | 2003-03-28 | Kakunai Juyotai Kenkyusho:Kk | 新規化粧品、新規外用剤及び新規浴剤の製造方法 |
| JP4568464B2 (ja) | 2001-11-07 | 2010-10-27 | 雪印乳業株式会社 | 記憶障害予防治療剤 |
| WO2004024180A1 (en) * | 2002-09-16 | 2004-03-25 | Agennix Incorporated | Lactoferrin compositions and methods of wound treatment |
| US20040214750A1 (en) * | 2003-04-28 | 2004-10-28 | Georgiades Izolda M. | Medicaments for healing skin conditions in humans |
| EP1937298A4 (en) | 2005-10-14 | 2009-11-11 | Auckland Uniservices Ltd | USE OF LACTOFERRIN FRAGMENTS AND HYDROLYSATES |
| JP2007246413A (ja) * | 2006-03-14 | 2007-09-27 | Snow Brand Milk Prod Co Ltd | 乳由来塩基性タンパク質含有組成物 |
| JP5087297B2 (ja) * | 2007-03-05 | 2012-12-05 | 森永乳業株式会社 | インターロイキン−１１産生促進剤 |
| AR066354A1 (es) * | 2007-05-01 | 2009-08-12 | Genzyme Corp | La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica |
| AU2008295449A1 (en) * | 2007-09-07 | 2009-03-12 | Industrial Research Limited | Agents with angiogenic and wound healing activity |
| ES2378213T3 (es) * | 2007-11-01 | 2012-04-10 | Megmilk Snow Brand Co., Ltd. | Material de alimento para inhibir la formación de osteoclastos |
| MY160058A (en) | 2007-11-01 | 2017-02-15 | Megmilk Snow Brand Co Ltd | Bone-reinforcing food material |
| NZ589308A (en) * | 2008-05-14 | 2012-11-30 | Agriculture Victoria Serv Pty | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
| JP5955499B2 (ja) | 2010-09-30 | 2016-07-20 | 雪印メグミルク株式会社 | 皮膚コラーゲン産生促進剤 |
| JP2012077018A (ja) | 2010-09-30 | 2012-04-19 | Snow Brand Milk Products Co Ltd | 皮膚コラーゲン産生促進剤 |
| CA2823505A1 (en) | 2011-01-26 | 2012-08-02 | Megmilk Snow Brand Co., Ltd. | Agent for improving peripheral sensitivity of skin |
| JP2013079216A (ja) * | 2011-10-04 | 2013-05-02 | Snow Brand Milk Products Co Ltd | 感覚改善剤 |
-
2012
- 2012-01-13 CA CA2823505A patent/CA2823505A1/en not_active Abandoned
- 2012-01-13 AU AU2012210013A patent/AU2012210013C1/en not_active Ceased
- 2012-01-13 MY MYPI2013701111A patent/MY162943A/en unknown
- 2012-01-13 JP JP2012554720A patent/JP5993308B2/ja active Active
- 2012-01-13 WO PCT/JP2012/050617 patent/WO2012102100A1/ja active Application Filing
- 2012-01-13 EP EP12739663.8A patent/EP2668956A4/en not_active Withdrawn
- 2012-01-13 KR KR1020137020954A patent/KR101748907B1/ko active IP Right Grant
- 2012-01-13 CN CN201280006644.0A patent/CN103370074B/zh not_active Expired - Fee Related
- 2012-01-13 US US13/981,698 patent/US20150064158A1/en not_active Abandoned
- 2012-01-18 TW TW101102016A patent/TWI562734B/zh not_active IP Right Cessation
-
2015
- 2015-09-10 US US14/850,485 patent/US9884095B2/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| Elagamy et al. Int. Dairy J, 1996, 6:129-145. * |
| Fee et al. Separation and Purification Technology, 2006, 48:143-149. * |
| Shin et al. "Identification of lactoperoxidase in mature human milk", J. Nutr.Biochem., 2000, 11:94-102. * |
| Tomita et al. "Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin", J Dairy Sci., 1991, 74:4137-4142. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9884095B2 (en) | 2011-01-26 | 2018-02-06 | Megmilk Snow Brand Co., Ltd. | Milk-derived basic protein fraction as skin sensitivity improving agent |
| AU2012319579B2 (en) * | 2011-10-04 | 2017-08-10 | Megmilk Snow Brand Co., Ltd. | Sense-improving agent |
| US9861121B2 (en) | 2013-03-28 | 2018-01-09 | Megmilk Snow Brand Co., Ltd. | Milk basic protein composition and production process therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2668956A1 (en) | 2013-12-04 |
| EP2668956A4 (en) | 2015-11-11 |
| AU2012210013C1 (en) | 2017-06-01 |
| KR101748907B1 (ko) | 2017-06-19 |
| JPWO2012102100A1 (ja) | 2014-06-30 |
| US9884095B2 (en) | 2018-02-06 |
| JP5993308B2 (ja) | 2016-09-14 |
| CA2823505A1 (en) | 2012-08-02 |
| AU2012210013B2 (en) | 2017-02-23 |
| TWI562734B (en) | 2016-12-21 |
| WO2012102100A1 (ja) | 2012-08-02 |
| CN103370074A (zh) | 2013-10-23 |
| CN103370074B (zh) | 2015-09-02 |
| TW201244644A (en) | 2012-11-16 |
| NZ613689A (en) | 2015-09-25 |
| US20150374797A1 (en) | 2015-12-31 |
| MY162943A (en) | 2017-07-31 |
| KR20140041427A (ko) | 2014-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0704218B1 (en) | Bone reinforcing agent and foods and drinks product containing the same | |
| US20110124606A1 (en) | Sense-improving agent | |
| JP3018313B2 (ja) | 骨形成促進及び骨吸収防止剤 | |
| US9884095B2 (en) | Milk-derived basic protein fraction as skin sensitivity improving agent | |
| CA2349980C (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| ES2378213T3 (es) | Material de alimento para inhibir la formación de osteoclastos | |
| US20100209412A1 (en) | Osteogenesis promoter | |
| PT2208735E (pt) | Matéria alimentar para promover a diferenciação de osteoblasto e inibir a diferenciação de osteoclasto | |
| US10016481B2 (en) | Sensation-improving agent | |
| EP1602284A1 (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| JP5311804B2 (ja) | 感覚改善剤 | |
| NZ613689B2 (en) | Agent for improving deteriorated peripheral sensation due to aging and/or disease | |
| EP3037100A1 (en) | Muscle-atrophy-preventing agent | |
| NZ623006B2 (en) | Sensation-improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MEGMILK SNOW BRAND CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KATOH, KEN;UEDA, NORIKO;UENO, HIROSHI;AND OTHERS;SIGNING DATES FROM 20130816 TO 20131018;REEL/FRAME:031778/0187 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |